Use of BCG in Immunotherapy of Superficial Bladder Cancer: Multicentric Investigation on Safety and Compliance
- 16 July 2003
- journal article
- Published by Taylor & Francis Ltd in UroOncology
- Vol. 2 (3), 129-135
- https://doi.org/10.1080/1561095021000037631
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Gender- and Smoking-Related Bladder Cancer RiskJNCI Journal of the National Cancer Institute, 2001
- Gender differences in stage-adjusted bladder cancer survivalUrology, 2000
- Gender differences in stage distribution of bladder cancerUrology, 2000
- Cigar Smoking in Men and Risk of Death From Tobacco-Related CancersJNCI Journal of the National Cancer Institute, 2000
- Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladderCancer, 1999
- The prognostic role of gender in survival of adult cancer patientsEuropean Journal of Cancer, 1998
- Smoking and urological diseasePerspectives in Public Health, 1998
- Impact of tumour grade, stage, number and size, and smoking and sex, on survival in patients with transitional cell carcinoma of the bladderBJU International, 1995
- Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder CancerJournal of Urology, 1992
- Systemic Bacillus Calmette-Guérin Infection, ‘BCGitis’, in Patients Treated by Intravesical Bacillus Calmette-Guérin Therapy for Bladder CancerEuropean Urology, 1989